Physician profile
Ellen Ball
NPI 1669933461
$1,727.17
in general payments reported to CMS, 2019-2025
24 companies · $826 in 2025
The $826 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $506 · 2022: $152 · 2023: $244 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.43 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $346.55 | 2021-2025 | Erleada |
| Astrazeneca Pharmaceuticals Lp | $191.60 | 2021 | |
| Myriad Genetic Laboratories, INC. | $181.14 | 2021-2023 | Myrisk |
| Gilead Sciences, INC. | $154.30 | 2022-2023 | Trodelvy |
| Sumitomo Pharma America, INC. | $146.44 | 2025 | Gemtesa, Orgovyx |
| Seagen INC. | $111.84 | 2021-2022 | |
| Antares Pharma, INC. | $82.86 | 2025 | Xyosted |
| Immunitybio, INC. | $69.44 | 2025 | |
| Endo USA, INC. | $60.24 | 2025 | Xiaflex |
| Pharmacyclics LLC, An Abbvie Company | $57.57 | 2021-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $56.32 | 2021-2025 | |
| Laborie Medical Technologies Corp. | $51.44 | 2025 | |
| 180 Medical, INC. | $22.98 | 2025 | Gentlecath |
| Procept Biorobotics Corporation | $21.97 | 2025 | |
| Celgene Corporation | $21.13 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.02 | 2023 | Jaypirca, Verzenio |
| Adc Therapeutics America, INC. | $19.75 | 2023 | |
| Amgen INC. | $19.43 | 2021 | |
| Abbvie INC. | $18.56 | 2021 | |
| Progenics Pharmaceuticals, INC. | $18.48 | 2025 | |
| Genzyme Corporation | $15.35 | 2021 | |
| Blueprint Medicines Corporation | $14.42 | 2021 | |
| Taiho Oncology, INC. | $13.05 | 2021 | |
| Incyte Corporation | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.